CRISPR/Cas 9 is a bacterial defense system for editing genomes that has been coined one of the most monumental biotechnologies since the discovery of the polymerase chain reaction (PCR). Since 2012, two research teams, one out of the University of California, Berkeley, and the other from both the Broad Institute and the Massachusetts Institute of Technology, have been battling an ongoing patent war. The US Patent and Trademark Office (USPTO) is left to decide who can claim the technology as their own.
This post was originally published on the Cardozo Journal of Conflict Resolution website on February 2, 2023. The original post can be accessed via the Archived Link button above.
Ben-Jacob, Shifra, "The Ongoing Patent Battle Over CRISPR/Cas-9" (2023). CJCR Blog. 47.